BioLineRx and Hemispherian Dose First Patient in Phase 1/2a GLIX1 Glioblastoma Trial

The latest announcement is out from Bioline RX Ltd Sponsored ADR ( (BLRX) ).

BioLineRx Ltd., a clinical-stage biopharmaceutical company specializing in oncology and rare diseases, is advancing GLIX1 as its lead asset, targeting DNA damage response in glioblastoma and other solid tumors, alongside its approved stem cell mobilization drug APHEXDA for multiple myeloma. The company develops GLIX1 in partnership with Hemispherian AS, a Norwegian oncology firm focused on first-in-class small-molecule cancer therapies.

On April 28, 2026, BioLineRx and Hemispherian reported that the first patient was dosed in a first-in-human Phase 1/2a trial of GLIX1 for recurrent and progressive glioblastoma and other high-grade gliomas, signaling a key operational milestone in their collaboration. The study, enrolling at U.S. centers including NYU Langone Health, will first establish a recommended dose in up to 30 patients before expanding into additional indications, potentially strengthening both companies’ positions in brain cancer therapeutics if GLIX1’s preclinical promise translates clinically.

GLIX1, an oral, first-in-class small molecule designed to activate TET2 and induce selective DNA damage in cancer cells, has shown potent anti-tumor activity, strong blood-brain-barrier penetration and a favorable safety profile in preclinical models. By focusing initially on glioblastoma, a highly aggressive and treatment-resistant tumor with suppressed TET2 activity, the program targets a major unmet need and could open broader opportunities across tumors where DNA damage repair is critical for cancer survival.

The Phase 1 dose-escalation segment will assess safety, pharmacokinetics, pharmacodynamics and preliminary efficacy, with data expected in the first half of 2027, and will determine a maximum tolerated or recommended dose. A planned Phase 2a expansion will explore newly diagnosed glioblastoma and selected other cancers, alone or combined with standard therapies such as PARP inhibitors, potentially laying the groundwork for accelerated later-stage development and enhancing BioLineRx’s and Hemispherian’s strategic positioning in oncology innovation.

The most recent analyst rating on (BLRX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Bioline RX Ltd Sponsored ADR stock, see the BLRX Stock Forecast page.

Spark’s Take on BLRX Stock

According to Spark, TipRanks’ AI Analyst, BLRX is a Neutral.

The score is held down primarily by weak financial performance—especially the steep 2025 revenue decline, continued losses, and persistent negative free cash flow. Technicals add additional pressure with a negative MACD and price below key longer-term moving averages. Valuation is not supportive due to negative earnings (negative P/E) and no dividend yield data.

To see Spark’s full report on BLRX stock, click here.

More about Bioline RX Ltd Sponsored ADR

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on oncology and rare diseases, with shares listed on NASDAQ and TASE under the ticker BLRX. Its lead development asset is GLIX1, a first-in-class oral small molecule targeting DNA damage response in glioblastoma and other solid tumors, while its first approved product, APHEXDA (motixafortide), is marketed for stem cell mobilization in multiple myeloma.

The company is collaborating with Norway-based Hemispherian AS, a clinical-stage oncology firm advancing first-in-class small-molecule cancer therapies, to develop GLIX1 for glioblastoma and a broader range of solid tumors. BioLineRx also retains rights to develop motixafortide in solid tumors, including metastatic pancreatic cancer, where a Phase 2b trial is ongoing with Columbia University.

Average Trading Volume: 13,490

Technical Sentiment Signal: Strong Sell

Current Market Cap: $11.41M

For a thorough assessment of BLRX stock, go to TipRanks’ Stock Analysis page.